HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer

被引：0
|
作者：
Alyamani, Mohammad [1 ]
Emamekhoo, Hamid [2 ]
Park, Sunho [1 ]
Taylor, Jennifer [1 ]
Almassi, Nima [1 ]
Upadhyay, Sunil [3 ]
Tyler, Allison [1 ]
Berk, Michael P. [1 ]
Hwang, Tae Hyun [1 ]
Grivas, Petros [1 ]
Rini, Brian [1 ]
Garcia, Jorge [1 ]
Auchus, Richard J. [3 ]
Sharifi, Nima [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Univ Michigan, Sch Med, Ann Arbor, MI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2572
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
    Shiota, Masaki
    Narita, Shintaro
    Akamatsu, Shusuke
    Fujimoto, Naohiro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Habuchi, Tomonori
    Ogawa, Osamu
    Eto, Masatoshi
    JAMA NETWORK OPEN, 2019, 2 (02) : e190115
  • [22] Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes
    Mckay, Rana R.
    Nelson, Tyler J.
    Pagadala, Meghana S.
    Teerlink, Craig C.
    Gao, Anthony
    Bryant, Alex K.
    Agiri, Fatai Y.
    Guram, Kripa
    Thompson, Reid F.
    Pridgen, Kathryn M.
    Seibert, Tyler M.
    Lee, Kyung Min
    Carter, Hannah
    Lynch, Julie A.
    Hauger, Richard L.
    Rose, Brent S.
    JAMA NETWORK OPEN, 2024, 7 (03) : E242976
  • [23] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Daniel Hettel
    Nima Sharifi
    Nature Reviews Urology, 2018, 15 : 191 - 196
  • [24] HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility
    Chang, BL
    Zheng, SQL
    Hawkins, GA
    Isaacs, SD
    Wiley, KE
    Turner, A
    Carpten, JD
    Bleecker, ER
    Walsh, PC
    Trent, JM
    Meyers, DA
    Isaacs, WB
    Xu, JF
    CANCER RESEARCH, 2002, 62 (06) : 1784 - 1789
  • [26] HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
    Sharifi, Nima
    Azad, Arun A.
    Patel, Mona
    Hearn, Jason W. D.
    Wozniak, Michele
    Zohren, Fabian
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    CELL REPORTS MEDICINE, 2024, 5 (08)
  • [27] HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
    Fei-fei Han
    Lu-lu Ren
    Ling-ling Xuan
    Ya-li LV
    He Liu
    Li-li Gong
    Zhuo-ling An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 103 - 112
  • [28] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Hettel, Daniel
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2018, 15 (03) : 191 - 196
  • [29] HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
    Han, Fei-Fei
    Ren, Lu-Lu
    Xuan, Ling-Ling
    Lv, Ya-Li
    Liu, He
    Gong, Li-Li
    An, Zhuo-Ling
    Liu, Li-Hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 103 - 112
  • [30] Response prediction with HSD3B1
    Thoma, Clemens
    NATURE REVIEWS UROLOGY, 2017, 14 (12) : 699 - 699
12345